- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30441
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
本帖最后由 StephenW 于 2011-4-3 11:18 编辑
interdetect 发表于 2011-4-3 10:36
2009 EASL(欧洲肝脏研究学会)乙肝诊治指南中涉及的三个乙肝治疗终点:(1) 对于HBeAg阳性和HBeAg阴性 ...
Good try, Interdetect. As I say, some people suspect(怀疑), but no proof(证明). Before 2009, it was very difficult to measure the quantity of HbSAg in the blood (it is still very difficult, despite the fact many hospitals in China are doing it. The reasons are: HbSAg particles and proteins are no homogeneous, I am quoting the experts). After Abbott and Roach systems become available, some scientists begin to measure quantity of HbSag during various stages of HBV infection (immune tolerance, immune clearance, HbeAg-ve carriers) and during treatment with Interferon. The relationship between hbvdna, HbSag quantity, and various stages are not simple. So scientists are still working on the hypothesis that :HbSag quantity is a surrogate marker for "transcriptional active" cccDNA.
Your arguments about not using HbeAg and HbcAg are not that good:
1. HbeAg appears then disappears and it is not part of the virus (it is produced only in an intermediate step, finally becomes the inner core of the various)
2. HbcAg - all hbvers, chronic or cured, all have the anti-body to HbcAg.
|
-
总评分: 现金 + 4
查看全部评分
|